Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival

Meletios A. Dimopoulos, Maria Roussou, Maria Gavriatopoulou, Despina Fotiou, Dimitrios Ziogas, Magdalini Migkou, Ioannis Panagiotidis, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Erasmia Psimenou, John N Boletis, Dimitra Bacharaki, Despoina Mparmparoussi, Charis Matsouka, Stavroula Giannouli, Evangelos Terpos, Efstathios Kastritis, MD

Blood (2016) 128 (22): 4492.

https://doi.org/10.1182/blood.V128.22.4492.4492

Published: 2016

Journal Articles

Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important

Meletios A Dimopoulos, Maria Roussou, Nikolaos Kanellias, Maria Gavriatopoulou, Magdalini Migkou, Ioannis Panagiotidis, Evangelos Eleutherakis-Papaiakovou, Dimitrios Ziogas, Despina Fotiou, Stavroula Giannouli, Panagiotis Tsirigotis, MD PhD, Christos Poziopoulos, Sossana Delimpasi, Despoina Mparmparoussi, Charis Matsouka, Kostas Konstantopoulos, Evangelos Terpos, Efstathios Kastritis, MD

Blood (2016) 128 (22): 3310.

https://doi.org/10.1182/blood.V128.22.3310.3310

Published: 2016

Journal Articles

Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy

Meletios A. Dimopoulos, Evangelos Terpos, Maria Gavriatopoulou, Despoina Kalapanida, Evangelos Eleutherakis-Papaiakovou, Maria Roussou, Despoina Mparmparoussi, Athanasios Zomas, Dimitra Gika, Zafiris Kartasis, Charis Matsouka, Evangelos Kostis, Sofoklis Kontogiannis, Kostas Konstantopoulos, Efstathios Kastritis, MD

Blood (2014) 124 (21): 4738.

https://doi.org/10.1182/blood.V124.21.4738.4738

Published: 2014

Journal Articles

Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment

Meletios A. Dimopoulos, Maria Roussou, Evangelos Terpos, Erasmia Psimenou, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Despoina Kalapanida, Marios Bakogeorgos, Despoina Mparmparoussi, Theodoros P. Vassilakopoulos, Dimitra Gika, Charis Matsouka, Ioannis Boletis, Kostas Konstantopoulos, Efstathios Kastritis, MD

Blood (2014) 124 (21): 4769.

https://doi.org/10.1182/blood.V124.21.4769.4769

Published: 2014

Journal Articles

Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents

Efstathios Kastritis, MD, Evangelos Terpos, Maria Gavriatopoulou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Marios Bakogeorgos, Despoina Kalapanida, Spyros Orfanopoulos, Vasiliki Bampali, Thaleia Meletiou, Dimitra Gika, Despoina Mparmparoussi, Charis Matsouka, Meletios A. Dimopoulos

Blood (2014) 124 (21): 3464.

https://doi.org/10.1182/blood.V124.21.3464.3464

Published: 2014

Journal Articles

Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction

Meletios A. Dimopoulos, MD, Evangelos Terpos, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Nikolaos Kanellias, Dimitrios Christoulas, Despoina Kalapanida, Despoina Mparmparoussi, Charis Matsouka, Sofoklis Kontogiannis, Evangelos Kostis, Erasmia Psimenou, Efstathios Kastritis

Blood (2013) 122 (21): 3176.

https://doi.org/10.1182/blood.V122.21.3176.3176

Published: 2013

Journal Articles

Very Early Death (<2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk Features Of Both The Disease and The Patient

Efstathios Kastritis, Evangelos Terpos, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Despoina Kalapanida, Magdalini Migkou, Nikolaos Kanellias, Dimitrios Christoulas, Dimitra Gika, Despoina Mparmparoussi, Charis Matsouka, Meletios A. Dimopoulos, MD

Blood (2013) 122 (21): 3195.

https://doi.org/10.1182/blood.V122.21.3195.3195

Published: 2013

Journal Articles

Greek Registry Of Essential Thrombocythemia: Baseline Characteristics and Therapeutic Strategy

Blood (2013) 122 (21): 4084.

https://doi.org/10.1182/blood.V122.21.4084.4084

Published: 2013

Journal Articles

A Shorter Time to First Treatment and Worst Overall survival Is Observed in Cll Patients with Reduced Serum IgM As Evaluated with Novel Serum Immunoassays

Blood (2012) 120 (21): 4585.

https://doi.org/10.1182/blood.V120.21.4585.4585

Published: 2012

Journal Articles

The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients,

Meletios A Dimopoulos, Maria Roussou, Maria Gkotzamanidou, Erasmia Psimenou, Despoina Mparmparoussi, Charis Matsouka, Evangelos Terpos, Efstathios Kastritis

Blood (2011) 118 (21): 3961.

https://doi.org/10.1182/blood.V118.21.3961.3961

Published: 2011

Journal Articles

Determination of the Percentage of CML Patients that Achieve Continuous Complete Molecular Response Under Treatment with TKIs and Are Eligible for Participation in a TKI Discontinuation Study

Blood (2011) 118 (21): 4446.

https://doi.org/10.1182/blood.V118.21.4446.4446

Published: 2011

Journal Articles

Elevated Serum Lactate Dehydrogenase (LDH) Should Be Included Among the Variables Which Define High Risk Multiple myeloma

Meletios A. Dimopoulos, Efstathios Kastritis, Maria Roussou, Maria Gkotzamanidou, Magdalini Migkou, Maria Gavriatopoulou, Dimitra Gika, Charis Matsouka, Despoina Mparmparoussi, Agapi Parcharidou, Evangelos Terpos

Blood (2010) 116 (21): 2969.

https://doi.org/10.1182/blood.V116.21.2969.2969

Published: 2010

Journal Articles

Renal Impairment Is Not An Independent Adverse Prognostic Factor In Multiple Myeloma Patients Who Are Treated Upfront with Novel Agent-Based Regimens

Meletios A. Dimopoulos, Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Maria Gkotzamanidou, Marina Iakovaki, Charis Matsouka, Despina Mparmparousi, Nikitas Nikitas, Dimitra Gika, Irene Grapsa, Erasmia Psimenou, Evangelos Terpos

Blood (2010) 116 (21): 3033.

https://doi.org/10.1182/blood.V116.21.3033.3033

Published: 2010

Journal Articles

Quantification of Serum IgMκ and IgMλ In Patients with Waldenstrom's Macroglobulinemia (WM) at Diagnosis and During Disease Course; Clinical Correlations

Efstathios Koulieris, Marie-Christine Kyrtsonis, Dimitris Maltezas, Tatiana Tzenou, Ladan Mirbahai, Nikolitsa Kafassi, Vassiliki Bartzis, Maria Dimou, George Georgiou, Charis Matsouka, Gerasimos Pangalis, Panayiotis Panayiotidis, Arthur Bradwell, FRCP, FRCPath, Stephen Harding, PhD

Blood (2010) 116 (21): 3004.

https://doi.org/10.1182/blood.V116.21.3004.3004

Published: 2010

Journal Articles

The Impact of Different Pre-Transplant Regimens Including Novel Agents On Peripheral Blood Mobilization, Harvest, Response and Survival in Patients Undergoing ASCT for Multiple Myeloma. A Single-Center Experience in 210 Patients.

Evangelos Eleutherakis-Papaiakovou, Dimitrios Christoulas, Magdalini Migkou, Maria Gavriatopoulou, Maria Roussou, Despina Mparmparoussi, Charis Matsouka, Efstathios Manios, Eleni Efstathiou, Efstathios Kastritis, Evangelos Terpos, Meletios A. Dimopoulos, Christos Papadimitriou

Blood (2009) 114 (22): 2279.

https://doi.org/10.1182/blood.V114.22.2279.2279

Published: 2009

Journal Articles

Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma and the Role of Novel Agents.

Maria Roussou, Efstathios Kastritis, Dimitrios Christoulas, Magdalini Migkou, Maria Gavriatopoulou, Charis Matsouka, Despina Mparmparoussi, Irini Grapsa, Erasmia Psimenou, Dimitra Gika, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2009) 114 (22): 955.

https://doi.org/10.1182/blood.V114.22.955.955

Published: 2009

Journal Articles

Antibacterial Prophylaxis Reduces the Incidence of Neutropenic Fever and the Rate of Infections in Patients with Multiple Myeloma Who Undergo An Autologous Stem Cell Transplantation.

Evangelos Eleutherakis-Papaiakovou, Evangelos Kostis, Dimitrios Christoulas, Magdalini Migkou, Maria Gavriatopoulou, Maria Roussou, Despina Mparmparoussi, Charis Matsouka, Efstathios Manios, Eleni Efstathiou, Efstathios Kastritis, Evangelos Terpos, Meletios A. Dimopoulos, Christos Papadimitriou

Blood (2009) 114 (22): 3334.

https://doi.org/10.1182/blood.V114.22.3334.3334

Published: 2009

Journal Articles

Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment.

Meletios A. Dimopoulos, Dimitrios Christoulas, Maria Roussou, Efstathios Kastritis, Magdalini Migkou, Maria Gavriatopoulou, Maria Gkotzamanidou, Marina Iakovaki, Charis Matsouka, Despina Mparmparoussi, Erasmia Psimenou, Irini Grapsa, Eleni Efstathiou, Evangelos Terpos

Blood (2009) 114 (22): 3871.

https://doi.org/10.1182/blood.V114.22.3871.3871

Published: 2009

Journal Articles

Reversibility of Renal Impairment of Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Identification of Predictive Factors.

Meletios A. Dimopoulos, Maria Roussou, Efstathios Kastritis, Maria Gavriatopoulou, Flora Zagouri, Magdalini Migkou, Charis Matsouka, Despina Barmparousi, Dimitrios Christoulas, Erasmia Psimenou, Irini Grapsa, Evangelos Terpos

Blood (2008) 112 (11): 1725.

https://doi.org/10.1182/blood.V112.11.1725.1725

Published: 2008

Journal Articles

Thalidomide Based Regimens (TBR) for Relapsed/Refractory Multiple Myeloma Patients: Long Term Follow Up, Unmaintained Remissions and Disease Control after Subsequent Treatments.

Maria Roussou, MD, Efstathios Kastritis, MD, Athanasios Anagnostopoulos, MD, Evangelos Eleftherakis-Papaiakovou, MD, Charis Matsouka, MD, Despina Barmparousi, MD, Magdalini Migkou, MD, Meletios Athanasios Dimopoulos, MD

Blood (2007) 110 (11): 4812.

https://doi.org/10.1182/blood.V110.11.4812.4812

Published: 2007

NARROW

Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival

Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important

Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy

Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment

Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents

Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction

Very Early Death (<2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk Features Of Both The Disease and The Patient

Greek Registry Of Essential Thrombocythemia: Baseline Characteristics and Therapeutic Strategy

A Shorter Time to First Treatment and Worst Overall survival Is Observed in Cll Patients with Reduced Serum IgM As Evaluated with Novel Serum Immunoassays

The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients,

Determination of the Percentage of CML Patients that Achieve Continuous Complete Molecular Response Under Treatment with TKIs and Are Eligible for Participation in a TKI Discontinuation Study

Elevated Serum Lactate Dehydrogenase (LDH) Should Be Included Among the Variables Which Define High Risk Multiple myeloma

Renal Impairment Is Not An Independent Adverse Prognostic Factor In Multiple Myeloma Patients Who Are Treated Upfront with Novel Agent-Based Regimens

Quantification of Serum IgMκ and IgMλ In Patients with Waldenstrom's Macroglobulinemia (WM) at Diagnosis and During Disease Course; Clinical Correlations

The Impact of Different Pre-Transplant Regimens Including Novel Agents On Peripheral Blood Mobilization, Harvest, Response and Survival in Patients Undergoing ASCT for Multiple Myeloma. A Single-Center Experience in 210 Patients.

Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma and the Role of Novel Agents.

Antibacterial Prophylaxis Reduces the Incidence of Neutropenic Fever and the Rate of Infections in Patients with Multiple Myeloma Who Undergo An Autologous Stem Cell Transplantation.

Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment.

Reversibility of Renal Impairment of Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Identification of Predictive Factors.

Thalidomide Based Regimens (TBR) for Relapsed/Refractory Multiple Myeloma Patients: Long Term Follow Up, Unmaintained Remissions and Disease Control after Subsequent Treatments.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only